Scoop Up These 2 ‘Strong Buy’ Healthcare Stocks Trading More Than 25% Below Their 52-Week Highs

NYSE: CO | Global Cord Blood Corporation  News, Ratings, and Charts

CO – The growing demand for healthcare services amid the COVID-19 pandemic has led to substantial capital inflows to the industry. Moreover, disruptive progress in genomics and smart healthcare is expected to be the next big thing. Given the industry’s solid growth prospects, we think fundamentally sound healthcare stocks Global Cord (CO) and IRIDEX (IRIX), which are currently trading at more than 25% below their 52-week price highs, could deliver significant returns. Let’s take a closer look at these names.

Healthcare spending has increased significantly in recent years, and currently accounts for more than 17% of U.S. GDP. The United States spends almost twice as much on healthcare as other nations. Healthcare companies’ crucial role in helping the world fight against coronavirus has led to significant capital inflows in the industry from governments and private organizations worldwide. 

The industry’s revenue increased 26.9% year-over-year and 6.7% sequentially in the second quarter of 2021. Moreover, the burgeoning genomics and healthcare technology segments are expected to revolutionize the industry in the near term.

So far, the industry has demonstrated immense growth potential, with significant progress in smart healthcare and innovative breakthroughs. Given the industry’s vitality and its growth prospects, we think that fundamentally sound healthcare stocks Global Cord Blood Corporation (CO) and IRIDEX Corporation (IRIX), which are currently trading more than 25% below their 52-week price highs, could be good bets now. These stocks are rated ‘Strong Buy’ in our proprietary POWR Ratings system.

Click here to checkout our Healthcare Sector Report for 2021

Global Cord Blood Corporation (CO)

Based in Hong Kong, CO provides umbilical cord blood storage and ancillary products. The company offers cord blood testing, processing, and storage services, and tests, processes, and stores donated cord blood, as well as providing matching services.

CO’s revenues increased 12.2% year-over-year to RMB315.17 million ($48.81 million) in its fiscal first quarter ended June 30. Its gross profit grew 12.6% from its  year-ago value to RMB267.33 million ($41.41 million), while its operating income improved 17.3% year-over-year to RMB156.56 million ($24.25 million). Its net income attributable to the company’s shareholders increased 3% year-over-year to RMB136.42 million ($21.13 million).

Shares of CO have gained 35.7% in price over the past year and 24% year-to-date to close yesterday’s trading session at $4.57. The stock is currently trading 27.6% below its 52-week high of $6.31.

It is no surprise that CO has an overall A rating, which equates to Strong Buy in our proprietary POWR Ratings system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

The stock also has an A grade for Quality, and a B grade for Value and Stability. Among the 57 stocks in the Medical – Diagnostics/Research industry, CO is ranked #3.

To see additional CO ratings for Sentiment, Growth, and Momentum, click here.

IRIDEX Corporation (IRIX)

IRIX in Mountain View, Calif., is an ophthalmic medical technology company that provides therapeutic-based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.

For its second fiscal quarter, ended July 3, IRIX’s revenue came in at $13.43 million, its highest level since 2007, reflecting a 116% increase from the same period last year. Its gross profit stood at a 14-year quarterly high of $6.11 million, up 153.9% year-over-year. Its net income grew 150.1% from its  year-ago value to $1.39 million. The company’s EPS increased 145% year-over-year to $0.09.

A $51.49 million consensus revenue estimate for the current year indicates a 41.7% increase year-over-year. The Street expects the company’s EPS to rise 41.3% in the current  year, versus  the last year. Moreover, IRIX has an impressive earnings surprise history also;  it beat the consensus EPS estimates in three out of the trailing four quarters.

IRIX gained 278.5% in price over the past year to close yesterday’s trading session at $7.22. The stock has gained 172.9% year-to-date. It is trading 25.6% below its 52-week high of $9.71.

IRIX has an overall A rating, which translates  to Strong Buy in our proprietary POWR Ratings system. IRIX has an A  grade  for Sentiment, and a B for Value and Quality. It is ranked #12 out of the 183 stocks in the Medical – Devices & Equipment industry.

Click here to view additional IRIX ratings for Growth, Momentum, and Stability.

Click here to checkout our Healthcare Sector Report for 2021


CO shares were trading at $4.61 per share on Friday morning, up $0.04 (+0.88%). Year-to-date, CO has gained 24.26%, versus a 19.65% rise in the benchmark S&P 500 index during the same period.


About the Author: Subhasree Kar


Subhasree’s keen interest in financial instruments led her to pursue a career as an investment analyst. After earning a Master’s degree in Economics, she gained knowledge of equity research and portfolio management at Finlatics. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
COGet RatingGet RatingGet Rating
IRIXGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Updated 2024 Stock Market Outlook

The bull market continues to rage on with the S&P 500 (SPY) making new highs. That is the past...the question is what does the future hold? That is why 44 year investment veteran Steve Reitmeister provides this updated 2024 Stock Market Outlook to help you carve a path to outperformance the rest of the year. Read on below for the full story...

Top 4 Tech Giants Poised for Explosive Growth

Fueled by the ever-growing demand for advanced technological solutions across various sectors and ongoing innovation, the tech industry has robust growth prospects. Thus, it could be wise to invest in top tech stocks Dropbox (DBX), TTM Technologies (TTMI), Lantronix (LTRX) and AstroNova (ALOT) for potential growth. Continue reading…

3 Top Rated Software Stocks to Streamline Your Investments

The software industry is thriving with soaring demand, presenting ample investment opportunities. So, fundamentally solid software stocks ServiceNow (NOW), Autodesk (ADSK), and Docebo (DCBO) might be ideal buys for promising returns. Read on...

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading...

Investor Alert: “Buy the Rumor, Sell the News!”

Everyone knows that the Fed is going to cut rates at some point this year. That is the worst kept secret on the planet helping to explain how we keep making new highs for the for the S&P 500 (SPY). Unfortunately that creates an interesting predicament for stocks after rates are cut. Plus another hurdle in the 2024 Presidential election. Steve Reitmeister is here to share his insights on the market outlook along with a preview of his top 12 stocks to outperform. Read on for more...

Read More Stories

More Global Cord Blood Corporation (CO) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CO News